Technology area: Biotechnology & Pharmaceuticals
29 pending office actions • 19 art units • 28 examiners • 0 of 29 (0%) have an AI response strategy ready • 25 patents granted in the last 365 days
The Research Institute AT Nationwide Children’S Hospital has 1 pending office action in the Medical Devices & Mechanical Engineering technology area. This single action is being examined within 1 distinct art unit, indicating a focused and singular point of contact with the patent office for its current pending matters. The prosecution is overseen by a single distinct examiner, which simplifies the interaction between the institute and the examining corps.
SABOKTAKIN, MARJAN is the examiner assigned to this case and is currently the busiest examiner. Because there is only a single pending action in the entire portfolio, the institute's immediate prosecution goals are entirely concentrated under SABOKTAKIN, MARJAN. This lack of diversity in examiners or art units means that the institute does not need to manage multiple simultaneous prosecution tracks or varying examiner requirements at this time. The resulting prosecution environment is one of high administrative simplicity and technical focus.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (3%) |
| §103 only | 6 (21%) |
| §102 only | 1 (3%) |
| §112 only | 2 (7%) |
| Double-patenting only | 2 (7%) |
| Double-patenting + other | 3 (10%) |
| Multi-statute (no §101) | 13 (45%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGA, KYLE THOMAS | 2 | 63.0% | +41.7% |
| WITTLIFF, KATERINA ANNA | 1 | 35.0% | +18.8% |
| FOLEY, SHANON A | 1 | 73.3% | +18.2% |
| HELLMAN, KRISTINA M | 1 | 65.1% | +55.5% |
| CHATTIN, AMY MARIE | 1 | 72.2% | +45.7% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| LANKFORD JR, LEON B | 1 | 70.0% | +31.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18859696 | GASTRIC SECRETION REINFUSION SYSTEM AND METHOD OF OPERATION | WITTLIFF, KATERINA ANNA | — |
| 18703595 | Neuregulin for Protection Against Respiratory Viral Infection and Post-Viral Disease | HELLMAN, KRISTINA M | — |
| 18686868 | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY PLATFORM | CHATTIN, AMY MARIE | — |
| 18290772 | INHIBITING INTRACELLULAR PATHOGENS | MOU, LIYUAN | — |
| 18483090 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USING HLA-F | BRETZ, COREY LANE | — |
| 18905388 | METHODS AND MATERIALS FOR GALGT2 GENE THERAPY | CANDELARIA, JULIANA IRENE | — |
| 18824806 | METHODS FOR DETERMINING ANTIBIOTIC SENSITIVITY | DICKENS, AMELIA NICOLE | — |
| 18712159 | CHIMERIC HSV EXPRESSING HIL21 TO BOOST ANTI-TUMOR IMMUNE ACTIVITY | MIANO, JOSEPH PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17271403 | CHIMERIC ONCOLYTIC HERPESVIRUS THAT STIMULATES AN ANTITUMOR IMMUNE RESPONSE | ALLEN, MICHAEL D | 61d |
| 18859696 | GASTRIC SECRETION REINFUSION SYSTEM AND METHOD OF OPERATION | WITTLIFF, KATERINA ANNA | — |
| 18780122 | METHODS AND MATERIALS FOR PRODUCING RECOMBINANT VIRUSES IN EUKARYOTIC MICROALGAE | FOLEY, SHANON A | — |
| 18703595 | Neuregulin for Protection Against Respiratory Viral Infection and Post-Viral Disease | HELLMAN, KRISTINA M | — |
| 18686868 | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY PLATFORM | CHATTIN, AMY MARIE | — |
| 18290772 | INHIBITING INTRACELLULAR PATHOGENS | MOU, LIYUAN | — |
| 18892143 | SYSTEMS AND METHODS FOR OPTIMIZED PATIENT SPECIFIC TISSUE ENGINEERING VASCULAR GRAFTS | LANKFORD JR, LEON B | — |
| 18287677 | PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | REGA, KYLE THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1636 | 5 |
| 1631 | 3 |
| 1671 | 2 |
| 1634 | 2 |
| 1657 | 2 |
| 1638 | 2 |
| 3783 | 1 |
| 1654 | 1 |
| 1643 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859696 | GASTRIC SECRETION REINFUSION SYSTEM AND METHOD OF OPERATION | WITTLIFF, KATERINA ANNA | 3783 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18780122 | METHODS AND MATERIALS FOR PRODUCING RECOMBINANT VIRUSES IN EUKARYOTIC MICROALGAE | FOLEY, SHANON A | 1671 | DP | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18703595 | Neuregulin for Protection Against Respiratory Viral Infection and Post-Viral Disease | HELLMAN, KRISTINA M | 1654 | §102§103§112 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18686868 | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY PLATFORM | CHATTIN, AMY MARIE | 1643 | §102§103§112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18290772 | INHIBITING INTRACELLULAR PATHOGENS | MOU, LIYUAN | 1628 | §102§103§112 | Non-Final OA | — | Pending | Jan 20, 2024 |
| 18483090 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USING HLA-F | BRETZ, COREY LANE | 1635 | §112 | Non-Final OA | — | Pending | Oct 09, 2023 |
| 17271403 | CHIMERIC ONCOLYTIC HERPESVIRUS THAT STIMULATES AN ANTITUMOR IMMUNE RESPONSE | ALLEN, MICHAEL D | 1671 | §112DP | Final Rejection | 61d | Pending | Feb 25, 2021 |
| 18905388 | METHODS AND MATERIALS FOR GALGT2 GENE THERAPY | CANDELARIA, JULIANA IRENE | 1634 | §102§103§112 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18892143 | SYSTEMS AND METHODS FOR OPTIMIZED PATIENT SPECIFIC TISSUE ENGINEERING VASCULAR GRAFTS | LANKFORD JR, LEON B | 1657 | DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18824806 | METHODS FOR DETERMINING ANTIBIOTIC SENSITIVITY | DICKENS, AMELIA NICOLE | 1645 | §102§112 | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18712159 | CHIMERIC HSV EXPRESSING HIL21 TO BOOST ANTI-TUMOR IMMUNE ACTIVITY | MIANO, JOSEPH PAUL | 1631 | §102§103§112 | Non-Final OA | — | Pending | May 21, 2024 |
| 18708777 | MATERIALS AND METHODS FOR SLC6A1 GENE THERAPY | KASAYAN, KATRIEL BARCELLANO | 1634 | §102§112Other | Non-Final OA | — | Pending | May 09, 2024 |
| 18573684 | METHODS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) | LAU, JONATHAN S | 1693 | §102§103 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18287677 | PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | — | Pending | Oct 20, 2023 |
| 18287682 | PRODUCTS AND METHODS FOR INDUCING EXON 2 SKIPPING OF THE DMD GENE IN TREATING MUSCULAR DYSTROPHY | SU-TOBON, QIWEN NMN | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18286923 | MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY | VIVLEMORE, TRACY ANN | 1638 | §103§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18281115 | USE OF TAMOXIFEN AND RELATED COMPOUNDS TO REDUCE BREAST IMPLANT CAPSULE FORMATION AND CAPSULAR CONTRACTURE | NGUYEN, NGOC-ANH THI | 1624 | §102§103 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18279169 | PRODUCTS AND METHODS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIES USING CRISPR-CAS9 TO CORRECT DMD EXON DUPLICATIONS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §102 | Non-Final OA | — | Pending | Aug 28, 2023 |
| 18273643 | MATERIALS AND METHODS FOR THE TREATMENT OF LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D) | MCKILLOP, JOHN CHARLES | 1637 | §101§102§103 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18246594 | PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | HUDSON, AMY ROSE | 1636 | §103§112 | Non-Final OA | — | Pending | Mar 24, 2023 |
| 17910992 | NK CELLS AND USES THEREOF FOR TREATMENT OF MICROBIAL INFECTIONS | WILSON, MICHAEL C | 1638 | Other | Non-Final OA | — | Pending | Sep 12, 2022 |
| 17426993 | ADENO-ASSOCIATED VIRUS DELIVERY OF CLN6 POLYNUCLEOTIDE | SPENCER, ANDREA LYNNE MORRIS | 1631 | §102§103DP | Final Rejection | — | Pending | Jul 22, 2022 |
| 17786721 | OPTIMIZED GENE THERAPY FOR TARGETING MUSCLE IN MUSCLE DISEASES | CHOWDHURY, IQBAL HOSSAIN | 1656 | §103 | Non-Final OA | 36d overdue | Pending | Jun 17, 2022 |
| 17641473 | ASSAY FOR IMMUNE CELL RECOVERY | GAO, ASHLEY HARTMAN | 1678 | §103 | Final Rejection | — | Pending | Mar 09, 2022 |
| 17632263 | EXON 44-TARGETED NUCLEIC ACIDS AND RECOMBINANT ADENO-ASSOCIATED VIRUS COMPRISING SAID NUCLEIC ACIDS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIES | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | — | Pending | Feb 02, 2022 |
| 17511187 | CHIMERIC ANTIGEN RECEPTOR (CAR) NK CELLS AND USES THEREOF | ZHU, JIANJIAN | 1631 | §112 | Final Rejection | 23d | Pending | Oct 26, 2021 |
| 17431270 | USE OF PLASMA MEMBRANE PARTICLES, LIPOSOMES, AND EXOSOMES TO ASSAY IMMUNE CELL POTENCY | SKOKO III, JOHN JOSEPH | 1600 | §103§112 | Non-Final OA | — | Pending | Aug 16, 2021 |
| 17265505 | PRENATAL PROBIOTIC FORMULATIONS | MISHRA, DEEPA | 1657 | §103Other | Non-Final OA | 96d overdue | Pending | Feb 02, 2021 |
| 17256640 | COMPOSITIONS AND METHODS FOR MEDIATING EPS | SIMMONS, CHRIS E | 1622 | §103 | Final Rejection | 75d | Pending | Dec 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialResearch Institute At Nationwide Children's Hospital has 29 pending office actions as of October 2026, spread across 19 art units and 28 examiners.
Kyle Thomas Rega has the most, with 2 of Research Institute At Nationwide Children's Hospital's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
